Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BVSNASDAQ:NVCRNASDAQ:TMDXNYSE:WRBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$9.61-4.6%$10.10$3.90▼$14.38$779.90M0.86419,843 shs526,102 shsNVCRNovoCure$20.06-2.7%$23.63$11.70▼$34.13$2.20B0.631.25 million shs617,207 shsTMDXTransMedics Group$64.35-4.1%$68.60$55.00▼$177.37$2.17B2.121.96 million shs794,679 shsWRBYWarby Parker$20.35-0.5%$25.14$11.35▼$28.68$2.11B1.911.89 million shs2.31 million shs10 Best Stocks to Own in 2025Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus-4.57%+1.59%-10.02%-12.87%+81.66%NVCRNovoCure-2.72%+4.15%-5.42%-39.96%+35.36%TMDXTransMedics Group-4.07%-1.44%-5.52%+0.14%-21.87%WRBYWarby Parker-0.35%-5.80%-20.98%-13.87%+76.97%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBVSBioventus3.2607 of 5 stars3.30.00.00.02.54.21.3NVCRNovoCure3.5872 of 5 stars3.31.00.04.52.91.70.0TMDXTransMedics Group3.0245 of 5 stars3.43.00.00.01.71.71.9WRBYWarby Parker3.0763 of 5 stars3.32.00.00.03.14.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 2.67Moderate Buy$15.0056.09% UpsideNVCRNovoCure 2.67Moderate Buy$32.6762.84% UpsideTMDXTransMedics Group 2.82Moderate Buy$122.7090.68% UpsideWRBYWarby Parker 2.69Moderate Buy$23.4315.12% UpsideCurrent Analyst Ratings BreakdownLatest BVS, NVCR, TMDX, and WRBY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/11/2025TMDXTransMedics GroupCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.00 ➝ $104.002/28/2025WRBYWarby ParkerCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform2/28/2025WRBYWarby ParkerUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $23.002/28/2025WRBYWarby ParkerRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$30.00 ➝ $32.002/27/2025WRBYWarby ParkerTelsey Advisory GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$28.00 ➝ $28.002/25/2025WRBYWarby ParkerRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$26.002/24/2025WRBYWarby ParkerRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy2/20/2025WRBYWarby ParkerTelsey Advisory GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$28.00 ➝ $28.002/5/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold2/5/2025WRBYWarby ParkerCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Sell$19.00 ➝ $23.001/21/2025WRBYWarby ParkerMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $23.00(Data available from 3/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$555.06M1.41$0.76 per share12.58$2.80 per share3.43NVCRNovoCure$605.22M3.64N/AN/A$3.39 per share5.92TMDXTransMedics Group$441.54M4.91$0.12 per share530.08$4.20 per share15.32WRBYWarby Parker$771.32M2.73N/AN/A$3.08 per share6.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus-$156.23M-$0.61N/A20.89N/A-7.11%15.61%4.01%N/ANVCRNovoCure-$207.04M-$1.56N/AN/AN/A-25.93%-41.48%-12.74%5/1/2025 (Estimated)TMDXTransMedics Group-$25.03M$1.0168.4645.00N/A8.14%18.74%4.39%4/29/2025 (Estimated)WRBYWarby Parker-$63.20M-$0.17N/A203.52N/A-4.39%-8.26%-4.37%5/8/2025 (Estimated)Latest BVS, NVCR, TMDX, and WRBY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/27/2025Q4 2024NVCRNovoCure-$0.34-$0.61-$0.27-$0.61$161.30 million$161.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/ATMDXTransMedics GroupN/AN/AN/AN/AN/AWRBYWarby ParkerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.851.410.99NVCRNovoCure0.271.491.44TMDXTransMedics Group2.428.207.33WRBYWarby ParkerN/A2.472.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%NVCRNovoCure84.61%TMDXTransMedics Group99.67%WRBYWarby Parker93.24%Insider OwnershipCompanyInsider OwnershipBVSBioventus32.90%NVCRNovoCure6.29%TMDXTransMedics Group7.00%WRBYWarby Parker26.55%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20081.16 million54.46 millionNot OptionableNVCRNovoCure1,320109.92 million101.40 millionOptionableTMDXTransMedics Group21033.66 million31.21 millionOptionableWRBYWarby Parker3,491103.62 million74.67 millionOptionableBVS, NVCR, TMDX, and WRBY HeadlinesRecent News About These CompaniesGreat Lakes Advisors LLC Acquires Shares of 602,895 Warby Parker Inc. (NYSE:WRBY)March 13 at 5:11 AM | marketbeat.comTarget stock tanks as it issues rough first quarter profit warning due to Trump tariffsMarch 10, 2025 | uk.finance.yahoo.comLisanti Capital Growth LLC Buys Shares of 241,840 Warby Parker Inc. (NYSE:WRBY)March 8, 2025 | marketbeat.comWarby Parker Inc. (NYSE:WRBY) CFO Sells $274,807.68 in StockMarch 7, 2025 | insidertrades.comWarby Parker Inc. (NYSE:WRBY) CFO Steven Clive Miller Sells 11,684 SharesMarch 7, 2025 | marketbeat.comBank of New York Mellon Corp Has $39.52 Million Stock Position in Warby Parker Inc. (NYSE:WRBY)March 7, 2025 | marketbeat.comNeil Harris Blumenthal Sells 27,967 Shares of Warby Parker Inc. (NYSE:WRBY) StockMarch 7, 2025 | marketbeat.comWarby Parker Inc. (NYSE:WRBY) CEO Neil Harris Blumenthal Sells 27,967 SharesMarch 6, 2025 | insidertrades.comBrokerages Set Warby Parker Inc. (NYSE:WRBY) Target Price at $23.43March 6, 2025 | americanbankingnews.comTarget issues rough first quarter profit warning due to Trump tariffsMarch 4, 2025 | aol.comWarby Parker Inc. (NYSE:WRBY) Given Average Rating of "Moderate Buy" by BrokeragesMarch 3, 2025 | marketbeat.comWarby Parker Inc. (NYSE:WRBY) Released Earnings Last Week And Analysts Lifted Their Price Target To US$27.36March 2, 2025 | finance.yahoo.comUBS Group Forecasts Strong Price Appreciation for Warby Parker (NYSE:WRBY) StockMarch 1, 2025 | marketbeat.comWarby Parker price target raised to $30 from $28 at Telsey AdvisoryMarch 1, 2025 | finance.yahoo.comRobert W. Baird Forecasts Strong Price Appreciation for Warby Parker (NYSE:WRBY) StockMarch 1, 2025 | marketbeat.comWarby Parker (NYSE:WRBY) Sees Strong Trading Volume - Here's What HappenedFebruary 28, 2025 | marketbeat.comTarget is bringing Warby Parker eyeglass shops to storesFebruary 28, 2025 | foxbusiness.comStifel Nicolaus Keeps Their Hold Rating on Warby Parker (WRBY)February 28, 2025 | markets.businessinsider.comWarby Parker (WRBY) Receives a Hold from Morgan StanleyFebruary 28, 2025 | markets.businessinsider.comWarby Parker (NYSE:WRBY) Posts Earnings Results, Misses Estimates By $0.08 EPSFebruary 28, 2025 | marketbeat.comWarby Parker (NYSE:WRBY) Receives Outperform Rating from Telsey Advisory GroupFebruary 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBVS, NVCR, TMDX, and WRBY Company DescriptionsBioventus NYSE:BVS$9.61 -0.46 (-4.57%) Closing price 03/13/2025 04:00 PM EasternExtended Trading$9.61 0.00 (0.00%) As of 03/13/2025 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.NovoCure NASDAQ:NVCR$20.06 -0.56 (-2.72%) Closing price 03/13/2025 04:00 PM EasternExtended Trading$20.11 +0.05 (+0.27%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.TransMedics Group NASDAQ:TMDX$64.35 -2.73 (-4.07%) Closing price 03/13/2025 04:00 PM EasternExtended Trading$64.48 +0.14 (+0.21%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.Warby Parker NYSE:WRBY$20.35 -0.11 (-0.53%) Closing price 03/13/2025 03:59 PM EasternExtended Trading$20.28 -0.07 (-0.35%) As of 03/13/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Deal With Archer Aviation Keeps AI’s Future in Focus Is a Bottom Finally Forming in Rocket Lab Stock? Intel Stock Surges on New CEO – The Real Story Runs Deeper AMD Stock: Can the PC Refresh Cycle Spark a Rally? Ramaco Resources Pins Hopes on Coal's Untapped Potential Nu Holdings: Is Brazil’s Fintech Leader a Buy at This Discount? Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
